216 related articles for article (PubMed ID: 35506019)
1. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA
Zhang SS; Ou SI
Lung Cancer (Auckl); 2022; 13():23-31. PubMed ID: 35506019
[TBL] [Abstract][Full Text] [Related]
2. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
Frampton JE
Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
[TBL] [Abstract][Full Text] [Related]
3. Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC.
Brazel D; Nagasaka M
Lung Cancer (Auckl); 2022; 13():47-52. PubMed ID: 35615402
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.
Wang J; Wu YL; Lu S; Wang Q; Li S; Zhong WZ; Wang Q; Li W; Wang B; Chen J; Cheng Y; Duan H; Li G; Shan L; Liu Y; Liu J; Huang X; Bolanos A; He J
JTO Clin Res Rep; 2024 Feb; 5(2):100621. PubMed ID: 38371194
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
[TBL] [Abstract][Full Text] [Related]
7. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.
Melosky B; Cheema P; Juergens RA; Leighl NB; Liu G; Wheatley-Price P; Sacher A; Snow S; Tsao MS; McLeod D; Chu Q
Ther Adv Med Oncol; 2021; 13():17588359211056306. PubMed ID: 34804219
[TBL] [Abstract][Full Text] [Related]
8. Overall Survival with Osimertinib in Resected
Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; Su WC; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Poole L; Bolanos A; Rukazenkov Y; Wu YL;
N Engl J Med; 2023 Jul; 389(2):137-147. PubMed ID: 37272535
[TBL] [Abstract][Full Text] [Related]
9. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
10. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
12. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T; Grohé C; Goldman JW; Shepherd FA; de Marinis F; Kato T; Wang Q; Su WC; Choi JH; Sriuranpong V; Melotti B; Fidler MJ; Chen J; Albayaty M; Stachowiak M; Taggart S; Wu YL; Tsuboi M; Herbst RS; Majem M
J Thorac Oncol; 2023 Sep; 18(9):1209-1221. PubMed ID: 37236398
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
Kris MG; Mitsudomi T; Peters S
Transl Lung Cancer Res; 2023 Apr; 12(4):824-836. PubMed ID: 37197636
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
17. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
Hardenberg MC; Patel B; Matthews C; Califano R; Garcia Campelo R; Grohe C; Hong MH; Liu G; Lu S; de Marinis F; Pérol M; Soo RA; Stiles BM; Tiseo M; Tsuboi M
ESMO Open; 2022 Oct; 7(5):100572. PubMed ID: 36108559
[TBL] [Abstract][Full Text] [Related]
18. The Role of Adjuvant Chemotherapy before Osimertinib in Epidermal Growth Factor Receptor Mutant Resected Non-Small Cell Lung Cancer and Communicating It to Patients.
Maione P; Salvi R; Gridelli C
Curr Oncol; 2024 Feb; 31(2):987-997. PubMed ID: 38392068
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib in Resected
Wu YL; Tsuboi M; He J; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS;
N Engl J Med; 2020 Oct; 383(18):1711-1723. PubMed ID: 32955177
[TBL] [Abstract][Full Text] [Related]
20. Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib.
Di Federico A; De Giglio A; Sperandi F; Melotti B; Ardizzoni A; Gelsomino F
Anticancer Drugs; 2024 Jan; 35(1):86-88. PubMed ID: 37227039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
